Literature DB >> 9207351

High-level resistance of cytomegalovirus to ganciclovir is associated with alterations in both the UL97 and DNA polymerase genes.

I L Smith1, J M Cherrington, R E Jiles, M D Fuller, W R Freeman, S A Spector.   

Abstract

Mutations in both the viral phosphotransferase gene, UL97, and the DNA polymerase gene, UL54, have been shown to confer ganciclovir resistance to cytomegalovirus (CMV). Moreover, UL54 alterations have been associated with in vitro cross-resistance of CMV to cidofovir. To investigate the relative significance of UL97 versus UL54 alterations in conferring antiviral resistance, phenotypic and genotypic characterization of 28 ganciclovir-resistant clinical CMV isolates was undertaken. Isolates were either low-level ganciclovir-resistant, which have ganciclovir ID50 values > or =8 microM and <30 microM and sensitivity to cidofovir, or high-level ganciclovir-resistant, which have ganciclovir ID50 values > or =30 microM and cross-resistance to cidofovir. Low-level ganciclovir-resistant isolates were associated with UL97 alterations and short periods of ganciclovir treatment, while high-level ganciclovir-resistant isolates were associated with both UL97 and polymerase alterations and were cultured after extended ganciclovir therapy.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9207351     DOI: 10.1086/514041

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  62 in total

1.  Limitations of cytomegalovirus testing.

Authors:  J Harmenberg; M Brytting
Journal:  Antimicrob Agents Chemother       Date:  1999-06       Impact factor: 5.191

2.  Recombinant green fluorescent protein-expressing human cytomegalovirus as a tool for screening antiviral agents.

Authors:  M Marschall; M Freitag; S Weiler; G Sorg; T Stamminger
Journal:  Antimicrob Agents Chemother       Date:  2000-06       Impact factor: 5.191

Review 3.  The role of DNA amplification technology in the diagnosis of infectious diseases.

Authors:  M Louie; L Louie; A E Simor
Journal:  CMAJ       Date:  2000-08-08       Impact factor: 8.262

4.  Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories.

Authors:  S Chou; N S Lurain; A Weinberg; G Y Cai; P L Sharma; C S Crumpacker
Journal:  Antimicrob Agents Chemother       Date:  1999-06       Impact factor: 5.191

Review 5.  Management of cytomegalovirus infection in solid organ transplantation.

Authors:  Camille N Kotton
Journal:  Nat Rev Nephrol       Date:  2010-10-26       Impact factor: 28.314

6.  Natural polymorphism of cytomegalovirus DNA polymerase lies in two nonconserved regions located between domains delta-C and II and between domains III and I.

Authors:  Anne-Marie Fillet; Laetitia Auray; Sophie Alain; Karine Gourlain; Berthe Marie Imbert; Fatiha Najioullah; Gael Champier; Stéphanie Gouarin; Jocelyne Carquin; Nadhira Houhou; Isabelle Garrigue; Alexandra Ducancelle; Danielle Thouvenot; Marie-Christine Mazeron
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

7.  Recombinant phenotyping of cytomegalovirus UL97 kinase sequence variants for ganciclovir resistance.

Authors:  Sunwen Chou
Journal:  Antimicrob Agents Chemother       Date:  2010-04-12       Impact factor: 5.191

8.  Cytomegalovirus retinitis and the acquired immunodeficiency syndrome--bench to bedside: LXVII Edward Jackson Memorial Lecture.

Authors:  Douglas A Jabs
Journal:  Am J Ophthalmol       Date:  2010-12-18       Impact factor: 5.258

9.  Characterization of the DNA- and dNTP-binding activities of the human cytomegalovirus DNA polymerase catalytic subunit UL54.

Authors:  Frédéric Picard-Jean; Isabelle Bougie; Martin Bisaillon
Journal:  Biochem J       Date:  2007-11-01       Impact factor: 3.857

Review 10.  Human cytomegalovirus resistance to antiviral drugs.

Authors:  C Gilbert; G Boivin
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.